| Members |
targetComponentId |
| Curettage of organ NOC NOS |
Scraping done with a curette |
| Curettage of organ NOC OS |
Scraping done with a curette |
| Curettage af graviditetsprodukter fra uterus, ikke klassificeret andetsteds |
Dilation of cervix uteri and curettage of products of conception from uterus |
| Curettage products conception: [uterus NEC (& retained)] or [termination NEC] |
Dilation of cervix uteri and curettage of products of conception from uterus |
| Curling esophagus |
Diffuse spasm of esophagus |
| kurvatur af rygsøjlen, ikke nærmere specificeret |
Curvature of spine |
| Curvature of spine NOS |
Curvature of spine |
| Curvature of stomach |
Stomach part |
| kutan CD30-positiv lymfoproliferativ sygdom |
Primary cutaneous CD30+ large T-cell lymphoma |
| kutant T-celle-lymfom |
Cutaneous T-cell lymphoma |
| Kutan anafylaksi |
Localised anaphylaxis |
| Kutan eruption |
Eruption |
| Cutaneous larva migrans NOS |
Cutaneous larva migrans |
| Cutaneous larva migrans NOS |
Cutaneous larva migrans |
| cyanocobalamin 25 µg næsespray |
Product containing only cyanocobalamin in nasal dose form (medicinal product form) |
| cyanocobalamin 500 µg næsespray |
Cyanocobalamin 500 microgram/actuation nasal spray |
| cyanocobalamin[57Co] 370kBq/ml oral opløsning |
Cyanocobalamin (57-Co) only product in oral dose form |
| cyanocobalamin[58Co] 370 kBq/ml oral opløsning |
Product containing only cyanocobalamin (58-Co) in oral dose form (medicinal product form) |
| CyberKnife |
Robotic radiation delivery system |
| cyklisk ødem |
Edema |
| cykloanæmisering |
Destruction of ciliary body |
| Cyclopentolate hydrochloride + phenylephrine hydrochloride |
Product containing cyclopentolate and phenylephrine (medicinal product) |
| Cyclopentolate hydrochloride 0.5% conventional release eye drops |
Cyclopentolate hydrochloride 5 mg/mL eye solution |
| cyclopentolathydrochlorid 0,5 % øjendråber til engangsbrug |
Cyclopentolate hydrochloride 5 mg/mL eye solution |
| Cyclopentolate hydrochloride 1% conventional release eye drops |
Cyclopentolate hydrochloride 10 mg/mL eye solution |
| cyclopentolathydrochlorid 1 % øjendråber til engangsbrug |
Cyclopentolate hydrochloride 10 mg/mL eye solution |
| cyclopentolathydrochlorid 2 % øjendråber |
Cyclopentolate hydrochloride 20 mg/mL eye solution |
| Cyclophosphamide 1g/vial injection |
Cyclophosphamide 1 g powder for solution for injection vial |
| Cyclophosphamide 1g/vial powder for injection |
Cyclophosphamide 1 g powder for solution for injection vial |
| Cyclophosphamide 200mg/vial injection |
Cyclophosphamide 200 mg powder for solution for injection vial |
| cyclophosphamid 200 mg/hætteglas pulver til injektionsvæske |
Cyclophosphamide 200 mg powder for solution for injection vial |
| cyclophosphamid 2 g/hætteglas injektionsvæske |
Product containing precisely cyclophosphamide 2 gram/1 vial powder for conventional release solution for injection (clinical drug) |
| Cyclophosphamide 500mg/vial injection |
Cyclophosphamide 500 mg powder for solution for injection vial |
| Cyclophosphamide 500mg/vial powder for injection |
Cyclophosphamide 500 mg powder for solution for injection vial |
| Cyclopropane [no agents] |
Cyclopropane |
| ciclosporin 50 mg/1 ml olieholdigt koncentrat til infusionsvæske |
Product containing precisely ciclosporin 50 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| ciclosporin 100 mg/5 ml opløsning |
Product containing only ciclosporin (medicinal product) |
| ciclosporin 100 mg/ml opløsning |
Ciclosporin 100 mg/mL oral solution |
| Cyclosporine 50mg gel |
Ciclosporin 50 mg oral capsule |
| ciclosporin 0,05 % øjenemulsion |
Product containing precisely ciclosporin 500 microgram/1 milliliter conventional release eye suspension (clinical drug) |
| Cylindrical cell papilloma uncertain whether benign or malignant |
Oncocytic Schneiderian papilloma of uncertain behavior (morphologic abnormality) |
| Cylindrocarpon tonkinense |
Neocosmospora lichenicola (organism) |
| cyproheptadinhydrochlorid 2 mg/5 ml syrup til oral anvendelse |
Product containing precisely cyproheptadine hydrochloride 400 microgram/1 milliliter conventional release oral solution (clinical drug) |
| Cyriax's syndrome |
Tietze's disease |
| Cyst of Bartholin's gland |
Cyst of Bartholin's gland duct |
| Cyst of bursa |
Bursal cyst (morphologic abnormality) |
| testiscyste |
Cyst of testis (disorder) |
| cysteamin 0,1 % øjendråber |
Product containing precisely mercaptamine 1 milligram/1 milliliter conventional release eye solution (clinical drug) |
| Cysteine carboxypeptidase |
Cysteine carboxypeptidase |
| Cysteine proteinase |
Cysteine proteinase |
| Cystic disease |
Fibrocystic change |
| Cystic fibrosis with other manifestations |
Cystic fibrosis |
| Cystic fibrosis with other manifestations |
Cystic fibrosis |
| cystocele med indvirkning på obstetrisk behandling og pleje |
Cystocele in pregnancy, childbirth and the puerperium |
| Cystography |
Fluoroscopic cystography (procedure) |
| Cystografi, ikke nærmere specificeret |
Cystography |
| Cystography NOS |
Cystography |
| Cystoskopisk eksstirpation af morfologisk forandring i blæren, ikke nærmere specificeret |
Cystoscopy and destruction of lesion of urinary bladder |
| Cystoscopy: [diagnostic NOS] or [unspecified check] |
Transurethral cystoscopy (procedure) |
| Cytarabine 100mg injection (pdr for recon)+diluent |
Product containing only cytarabine in parenteral dose form (medicinal product form) |
| cytarabin 100 mg pulver til injektionsvæske, opløsning, hætteglas |
Product containing only cytarabine in parenteral dose form (medicinal product form) |
| Cytarabine 1g injection (pdr for recon)+diluent |
Product containing only cytarabine in parenteral dose form (medicinal product form) |
| cytarabin 1 g pulver til injektionsvæske, opløsning, hætteglas |
Product containing only cytarabine in parenteral dose form (medicinal product form) |
| cytochrom P450 CYP2C9-enzymmangel |
Cytochrome P450 family 2 subfamily C member 9 poor metabolizer (finding) |
| cytochrom P450 CYP2D6-enzymmangel |
Cytochrome P450 family 2 subfamily D member 6 poor metabolizer (finding) |
| Cytochrome-b reductase deficiency |
Dihydrolipoamide dehydrogenase deficiency |
| Cytology of organ NOC |
Cytologic test (procedure) |
| Cytology of organ NOC NOS |
Cytologic test (procedure) |
| cytopatologisk procedure eller service |
Cytopathology procedure |
| Cytophaga uliginosa |
Zobellia uliginosa (organism) |
| cytostatisk middel |
Cytotoxic |
| Cytotoxic agent |
Cytotoxic |
| Cytotoxic drug therapy NOS |
The treatment of disease using chemical agents or drugs that are selectively toxic to the causative agent of the disease, such as a virus, bacterium, or other microorganism. |
| Cytotoxic drug therapy NOS |
The treatment of disease using chemical agents or drugs that are selectively toxic to the causative agent of the disease, such as a virus, bacterium, or other microorganism. |
| Cytotoxic injection NOS |
Administration using positive pressure and a needle or other equipment to drive a substance into the body. |
| Cytotoxic injection NOS |
Administration using positive pressure and a needle or other equipment to drive a substance into the body. |
| DF-1 Group |
Capnocytophaga ochracea |
| DHSS medical examination NOS |
Specialized medical examination |
| DS1500 attendance allowance NOS |
Attendance allowance medical (procedure) |
| undersøgelse ifm. attendance allowance-ordningen, DS1500 |
Attendance allowance medical (procedure) |
| DS4 attend allowance exam NOS |
Attendance allowance medical (procedure) |
| Dacarbazine 200mg/vial injection |
Product containing precisely dacarbazine (as dacarbazine citrate) 200 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
| Daclizumab 25mg/5 mL solution |
Daclizumab only product in parenteral dose form |
| Daclizumab 25mg/5mL conventional release solution for injection |
Daclizumab only product in parenteral dose form |
| daclizumab 25 mg/5 ml koncentrat til infusionsvæske |
Daclizumab only product in parenteral dose form |
| Dacron |
Polyethylene terephthalate (substance) |
| dakryocystorinostomi og indsættelse af tube, uanset yderligere specifikation |
Dacryocystorhinostomy and insertion of tube |
| Dactylaria constricta var constricta |
Ochroconis constricta |
| Daily |
Daily |
| Daily life psychotherapy NOS |
Daily life psychotherapy |
| Daily life psychotherapy NOS |
Daily life psychotherapy |
| Daily life rehabilitation NOS |
Daily life rehabilitation |
| Daily life rehabilitation NOS |
Daily life rehabilitation |
| Daktarin oral gel 15g |
Product manufactured as oromucosal dose form (product) |
| Skade på bækkenorgan eller -væv , ikke nærmere specificeret, efter mislykket graviditet |
Damage to pelvic organs or tissues following abortive pregnancy |
| Damage to pelvic organ or tissues NOS following abortive pregnancy |
Damage to pelvic organs or tissues following abortive pregnancy |
| Damaliscus dorcas |
Damaliscus pygargus (organism) |
| Damp environment |
Damp environment |
| Danaparoid sodium |
Product containing danaparoid (medicinal product) |
| bivirkning af danaparoidnatrium |
Adverse reaction to danaparoid (disorder) |
| allergi over for danaparoidnatrium |
Allergy to danaparoid (finding) |